Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer

被引:68
|
作者
Larsen, Signe Benzon [1 ]
Dehlendorff, Christian [1 ]
Skriver, Charlotte [1 ]
Dalton, Susanne Oksbjerg [1 ]
Jespersen, Christina Gade [1 ,4 ,5 ]
Borre, Michael [5 ]
Brasso, Klaus [2 ]
Norgaard, Mette [5 ]
Johansen, Christoffer [2 ]
Sorensen, Henrik Toft [5 ]
Hallas, Jesper [6 ]
Friis, Soren [1 ,3 ,5 ]
机构
[1] Danish Canc Soc, Res Ctr, Strandblvd 49, DK-2100 Copenhagen O, Denmark
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Univ Copenhagen, Copenhagen, Denmark
[4] Viborg Hosp, Viborg, Denmark
[5] Aarhus Univ Hosp, Aarhus, Denmark
[6] Univ Southern Denmark, Odense, Denmark
关键词
RISK; SUBDISTRIBUTION; RECURRENCE; OUTCOMES; QUALITY; OBESITY;
D O I
10.1200/JCO.2016.71.8981
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Increasing evidence indicates that statin use may reduce mortality from prostate cancer. In this work, we examined whether postdiagnosis statin use was associated with reduced cancer-specific mortality or all-cause mortality among patients with prostate cancer in Denmark. Material and Methods From nationwide Danish registries, we identified all patients with incident prostate adenocarcinoma from 1998 to 2011 and retrieved data on tumor and patient characteristics, drug use, and primary treatment. We defined postdiagnosis use (two or more prescriptions) of statins as a time-varying covariate with 1-year lag. Cox proportional hazards regression models used to compute hazard ratios (HRs) for prostate cancer-specific mortality and all-cause mortality through 2013 associated with postdiagnosis statin use. In secondary and sensitivity analyses, we assessed statin use within exposure periods of 1 year or 5 years after prostate cancer diagnosis and evaluated the influence of prediagnosis statin use. Results Among 31,790 patients, 7,365 died of prostate cancer and 11,811 died from other causes during a median follow-up of 2.8 years (interquartile range, 1.3 to 5.1 years) from 1 year after diagnosis. Postdiagnosis statin use was associated with adjusted HRs of 0.83 (95% CI, 0.77 to 0.89) for prostate cancer mortality and 0.81 (95% CI, 0.76 to 0.85) for all-cause mortality. Similar results were observed in 1-year and 5-year sensitivity analyses. No substantial effect measure modification was found with estimated dose or type of statin, clinical stage, Gleason score, or with prediagnosis statin use; however, patients who were diagnosed early in the study period or who underwent radical prostatectomy or endocrine therapy exhibited slightly lower HRs for prostate cancer mortality with postdiagnosis statin use than did those in the overall analyses. Conclusion Postdiagnosis statin use was associated with reduced mortality from prostate cancer; however, it remains to be established whether this association is causal.
引用
收藏
页码:3290 / +
页数:12
相关论文
共 50 条
  • [1] POSTDIAGNOSIS STATIN USE REDUCES MORTALITY
    Thoma, Clemens
    [J]. NATURE REVIEWS UROLOGY, 2017, 14 (10) : 582 - 582
  • [2] Postdiagnosis statin use reduces mortality
    Clemens Thoma
    [J]. Nature Reviews Urology, 2017, 14 : 582 - 582
  • [3] Statin use and mortality of patients with prostate cancer: a meta-analysis
    Meng, Yang
    Liao, Yan-Biao
    Xu, Peng
    Wei, Wu-Ran
    Wang, Jia
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 1689 - 1696
  • [4] Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study
    Sperling, Cecilie D.
    Verdoodt, Freija
    Hansen, Merete Kjaer
    Dehlendorff, Christian
    Friis, Soren
    Kjaer, Susanne K.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (11) : 2668 - 2676
  • [5] Associations of Statin Use With Colorectal Cancer Recurrence and Mortality in a Danish Cohort
    Lash, Timothy L.
    Riis, Anders H.
    Ostenfeld, Eva B.
    Erichsen, Rune
    Vyberg, Mogens
    Ahern, Thomas P.
    Thorlacius-Ussing, Ole
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2017, 186 (06) : 679 - 687
  • [6] Statin Use is Associated With Lower Mortality in Patients With Breast Cancer
    Oren, Ohad
    Yang, Eric H.
    Halfdanarson, Thorvardur R.
    Fischer, Karen M.
    Grill, Diane E.
    Kopecky, Stephen L.
    [J]. CIRCULATION, 2019, 140
  • [7] A Review of Statin Use and Prostate Cancer
    Pon, Doreen
    Abe, Andrew
    Gupta, Eric K.
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (02) : 1 - 8
  • [8] Statin use and the risk of prostate cancer
    Ho, Wei
    Choo, Dan-Wei
    Wu, Yi-Jung
    Lin, Yu-Sheng
    Chen, Bing-Jyue
    Hu, Chuan-Shen
    Wang, Jui
    Wang, Yu-Wen
    Chen, Po-Yu
    Chan, Ting-Fang
    Lin, Zhen-Fang
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 315 - 316
  • [9] Statin Use in Prostate Cancer: An Update
    Babcook, Melissa A.
    Joshi, Aditya
    Montellano, Jeniece A.
    Shankar, Eswar
    Gupta, Sanjay
    [J]. NUTRITION AND METABOLIC INSIGHTS, 2016, 9 : 43 - 50
  • [10] A Review of Statin Use and Prostate Cancer
    Doreen Pon
    Andrew Abe
    Eric K. Gupta
    [J]. Current Atherosclerosis Reports, 2015, 17